Nevertheless, it was of interest to note that tau expression was proposed as an effective predictor for breast cancer sensitivity to taxanes-based neoadjuvant chemotherapy, especially in the ER+ subgroups55, 56, 57, 58, our study could shed new light on the molecular mechanism underlying the utility of tau for individualizing adjuvant chemotherapy in breast cancer patients. This evidence concerns the gene ESR1 and breast cancer.